Charles River Laboratories International, Inc. CRL
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Charles River Laboratories International, Inc. (CRL) Shares outstanding
Charles River Laboratories International, Inc.'s shares outstanding at the end of fiscal 2025 was $49.6M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $48.0M. Over the past ten years it has ranged from $47.6M (fiscal 2015) to $51.6M (fiscal 2024); the current reading is higher than 45% of that period. Charles River Laboratories International, Inc. ranks 29th of 52 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Annual
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $49.6M | (4.00%) |
| FY2024 | $51.6M | 0.34% |
| FY2023 | $51.5M | 0.29% |
| FY2022 | $51.3M | (0.24%) |
| FY2021 | $51.4M | 1.61% |
| FY2020 | $50.6M | 1.85% |
| FY2019 | $49.7M | 1.38% |
| FY2018 | $49.0M | 0.93% |
| FY2017 | $48.6M | 1.26% |
| FY2016 | $48.0M | 0.68% |
Quarterly
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $48.0M | (1.90%) |
| Mar 2026 | $49.0M | (1.24%) |
| Dec 2025 | $49.6M | 0.28% |
| Sep 2025 | $49.4M | 0.22% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| QGEN QIAGEN N.V. compare | $207.8M |
| GH Guardant Health, Inc. compare | $132.9M |
| DGX Quest Diagnostics Incorporated compare | $112.0M |
| RVTY Revvity Inc. compare | $111.6M |
| LH Labcorp Holdings Inc. compare | $82.0M |
| ICLR ICON PLC compare | $77.4M |
| TWST Twist Bioscience Corporation compare | $62.4M |
| CRL Charles River Laboratories International, Inc. | $48.0M |
| MEDP Medpace Holdings, Inc. compare | $28.6M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CRL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- The full statement